Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 3.26% | 201.96 | 1.2% | $535.88m | |
| GILD | Gilead Sciences, Inc. | 4.53% | 76.08 | 0.9% | $480.62m | |
| BIIB | Biogen Inc. | 2.82% | 337.66 | 1.3% | $395.49m | |
| CELG | Celgene Corporation | 2.79% | 84.11 | 1.2% | $348.63m | |
| ILMN | Illumina, Inc. | 4.01% | 325.97 | 3.5% | $309.58m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 5.26% | 397.40 | 2.6% | $240.50m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 4.95% | 127.50 | 2.0% | $225.72m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 4.25% | 185.20 | 1.9% | $219.43m | |
| SRPT | Sarepta Therapeutics, Inc. | 5.20% | 138.17 | 16.4% | $180.01m | |
| A | Agilent Technologies, Inc. | 2.64% | 67.36 | 1.5% | $161.63m | |
| BMRN | BioMarin Pharmaceutical Inc. | 6.36% | 105.78 | 4.4% | $143.99m | |
| LGND | Ligand Pharmaceuticals Incorporated | 6.03% | 212.14 | 23.3% | $122.32m | |
| VKTX | Viking Therapeutics, Inc. | 6.51% | 15.13 | 0.9% | $119.37m | |
| NKTR | Nektar Therapeutics | 2.30% | 50.21 | 5.6% | $111.56m | |
| EXAS | Exact Sciences Corporation | 2.90% | 67.68 | 25.3% | $106.01m |
Company Profile
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.